Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Janssen Pharmaceutica

Ortho-muniel Pharmaceutical, Inc.

Keith T Demarest

Gee-Hong Kuo

Bruce Ray Conway

Patricia Pelton

Bruce E Maryanoff

Aihua Wang

Alan Deangelis

Han-Cheng Zhang

Hong Ye

Lan Shen

Rui Zhang

David F McComsey

Xiaoli Chen

Philip J Rybczynski

Catherine P Prouty

David John O'Neill

Kimberly White

Jacqueline C Bussolari

Joseph Gunnet

Thomas A Rano

Hamish N M Ross

Rafael Severino

Mona Patel

Yan Zhang

Michael J Costanzo

Min Amy Xiang

Leonard Robert Hecker

Stephen C Yabut

Yin Liang

Songfeng Lu

Richard Look

Bruce R Conway

Hamish N Ross

Peter J Connolly

William V Murray

Maud J Urbanski

Jay M Matthews

John H Dodd

Fengbin Song

Jung S Lee

Geoffrey R Heintzelman

Paul F Jackson

Ellen Sieber-McMaster

Kristin M Averill

Tonya L Martin

Han Cheng Zhang

Yuting Tang

Chandra R Shah

Joseph W Gunnet, Jr

James M Lenhard

Gregory C Leo

Kuo Gee-Hong

Min A Xiang

Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R, R, R, R, R, A, and Z, are defined herein.

GPR40 agonists in anti-diabetic drug combinations

The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol

Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.

4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators

Presented here are methods using alpha-methylglucoside (AMG) in vivo as an indicator for glucose absorption from the gastrointestinal (GI) system or glucose excretion in the urine after oral administration of AMG. The methods find use in, for example, but not limited to, determining the effect of a sodium-dependent glucose transporter (SGLT) inhibitor in an animal, comparing the differences in the effects of a first and second SGLT inhibitor in an animal, and diagnosing a disease associated with glucose absorption from the gastrointestinal (GI) system or glucose excretion from the kidney in an animal.

Methods of using alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

Substituted spiroheterocycles

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.

Substituted pyrroline kinase inhibitors

3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

Growing community of inventors

Flemington, NJ, United States of America

Keith T Demarest